61
James Arthur Hoffmann: GLP-1 formulations. Eli Lilly and Company, Mark J Stewart, Gregory A Cox, March 19, 2002: US06358924 (80 worldwide citation)

Methods and formulations are presented that provide for a) the oral absorption of GLP-1 peptides that bind surfactants; and b) long-term storage of formulations containing these peptides. For example, a GLP-1/DSS complex is administered orally instead of parenterally, which is much more convenient f ...


62
Robert J Sweeney: Defibrillation method. Eli Lilly and Company, Douglas J Taylor, Leroy Whitaker, March 5, 1991: US04996984 (80 worldwide citation)

The present invention provides a method for defibrillating a mammal in need of defibrillation employing multiple bursts of electrical current delivered to the mammal, the timing between said bursts being based upon the mammal's fibrillation cycle length.


63

64
Michael Rosario DeFelippis, Michael Allen Dobbins, Bruce Hill Frank, Shun Li, Dawn Marie Rebhun: Stable insulin formulations. Eli Lilly and Company, Mark J Stewart, March 7, 2000: US06034054 (79 worldwide citation)

The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requ ...


65
Willem P C Stemmer: Enzymatic inverse polymerase chain reaction library mutagenesis. Eli Lilly and Company, Knobbe Martens Olson & Bear, April 30, 1996: US05512463 (79 worldwide citation)

This invention discloses a method for generating a recombinant library by introducing one or more changes within a predetermined region of double-stranded nucleic acid, comprising providing a first primer population and a second primer population, each of the populations having a variable base compo ...


66
Jose De Leon, Thomas H Ferguson, Daniel S Skinner Jr: Method of making antimicrobial coated implants. Eli Lilly and Company, Steven R Lammert, Leroy Whitaker, August 28, 1990: US04952419 (78 worldwide citation)

Uniform adherent coatings of antimicrobial agents are applied to the surface of implants by applying a film of silicone oil to the surface of the implant and then contacting the film-bearing surface with antimicrobial agents in a film-adherent powder form. A durable antimicrobial coating is formed. ...


67
Steven Witt Dodd, Kenneth Francis Mace, Michael Ernst Trautmann: Chronic treatment regimen using glucagon-like insulinotropic peptides. Eli Lilly and Company, Alejandro Martinez, Gregory A Cox, August 21, 2007: US07259233 (78 worldwide citation)

The present invention encompasses a method of treating a disease by maintaining chronic steady state serum levels of a GLP-1 compound within a specified range.


68
Suad Efendic: Use of GLP-1 or analogs in treatment of myocardial infarction. Eli Lilly and Company, Mark J Stewart, James J Kelley, August 21, 2001: US06277819 (78 worldwide citation)

This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.


69
Michele C Smith, Charles Pidgeon: Process for purifying proteins and compounds useful in such process. Eli Lilly and Company, William C Martens, Arthur R Whale, February 11, 1986: US04569794 (76 worldwide citation)

This invention describes a process for separating a biologically active polypeptide or protein in the form of its precursor from a mixture containing said precursor and impurities, which comprises contacting said precursor with a resin containing immobilized metal ions, said precursor comprising the ...


70
Glaesner Wolfgang, Millican Rohn Lee Jr, Tian Yu, Tschang Sheng Hung Rainbow, Vick Andrew Mark: Fusion proteins. Eli Lilly And Company, Glaesner Wolfgang, Millican Rohn Lee Jr, Tian Yu, Tschang Sheng Hung Rainbow, Vick Andrew Mark, COX Gregory A, December 23, 2004: WO/2004/110472 (76 worldwide citation)

The invention provides active therapeutic peptides fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, reduced half antibody formation, and reduced effector activity, while not being immunogenic. The fusion proteins are useful in treating human diseases as well ...